GLAUKOS CorpGKOSEarnings & Financial Report
Glaukos Corp is a medical technology company focused on ophthalmology, developing and commercializing minimally invasive surgical devices, prescription pharmaceuticals and consumer products for glaucoma, corneal diseases and other eye disorders. It operates primarily across North America, Europe and Asia Pacific, serving hospitals, ophthalmology clinics and patients worldwide.
Revenue
$95.7M
Gross Profit
$73.1M
Operating Profit
$-30.0M
Net Profit
$-50.5M
Gross Margin
76.4%
Operating Margin
-31.3%
Net Margin
-52.8%
YoY Growth
19.0%
EPS
$-1.00
Financial Flow
GLAUKOS Corp Q2 2024 Financial Summary
GLAUKOS Corp reported revenue of $95.7M (up 19.0% YoY) for Q2 2024, with a net profit of $-50.5M (down 54.0% YoY) (-52.8% margin). Cost of goods sold was $22.6M, operating expenses totaled $103.1M.
Key Financial Metrics
| Total Revenue | $95.7M |
|---|---|
| Net Profit | $-50.5M |
| Gross Margin | 76.4% |
| Operating Margin | -31.3% |
| Report Period | Q2 2024 |
Revenue Breakdown
GLAUKOS Corp Q2 2024 revenue of $95.7M breaks down across 3 segments, led by Glaucoma at $49.8M (52.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Glaucoma | $49.8M | 52.0% |
| Other | $28.9M | 30.2% |
| Corneal Health | $17.1M | 17.8% |
GLAUKOS Corp Revenue by Segment — Quarterly Trend
GLAUKOS Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Glaucoma and Other) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Glaucoma | $86.4M | $80.8M | $72.3M | $59.1M |
| Other | $35.1M | $32.1M | $33.6M | $31.6M |
| Corneal Health | $21.6M | $20.6M | $18.2M | $15.9M |
GLAUKOS Corp Annual Revenue by Year
GLAUKOS Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $507.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $507.4M |
| 2024 | $383.5M |
| 2023 | $314.7M |
| 2022 | $282.9M |
GLAUKOS Corp Quarterly Revenue & Net Profit History
GLAUKOS Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $143.1M | +35.7% | $-133.7M | -93.4% |
| Q3 2025 | $133.5M | +38.1% | $-16.2M | -12.2% |
| Q2 2025 | $124.1M | +29.7% | $-19.7M | -15.8% |
| Q1 2025 | $106.7M | +24.6% | $-18.1M | -17.0% |
| Q4 2024 | $105.5M | +28.1% | $-33.6M | -31.8% |
| Q3 2024 | $96.7M | +23.9% | $-21.4M | -22.1% |
| Q2 2024 | $95.7M | +19.0% | $-50.5M | -52.8% |
| Q1 2024 | $85.6M | +15.9% | $-40.8M | -47.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $85.6M | $95.7M | $96.7M | $105.5M | $106.7M | $124.1M | $133.5M | $143.1M |
| YoY Growth | 15.9% | 19.0% | 23.9% | 28.1% | 24.6% | 29.7% | 38.1% | 35.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $933.3M | $919.7M | $926.5M | $974.8M | $966.2M | $987.0M | $999.4M | $893.5M |
| Liabilities | $482.6M | $254.5M | $258.0M | $207.8M | $202.2M | $221.8M | $229.8M | $237.3M |
| Equity | $450.7M | $665.2M | $668.5M | $766.9M | $764.0M | $765.1M | $769.5M | $656.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-33.9M | $-18.4M | $-9.6M | $507000 | $-18.5M | $7.0M | $-10.1M | $6.8M |